Evidence map›Paper›PMID 37577607›Full record

ArticleResearch square2023

Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19.

Lucile P A Neyton, Ravi K Patel, Aartik Sarma, UCSF COMET Consortium, Andrew Willmore, Sidney C Haller, Kirsten N Kangelaris, Walter L Eckalbar, David J Erle, Matthew F Krummel and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 1 institution in 2 countries.

Lucile P A NeytonDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, CA, USA.
Ravi K PatelUCSF CoLabs, University of California San Francisco, San Francisco, CA, USA.
Aartik SarmaDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0002-7508-7345
UCSF COMET Consortium
Andrew WillmoreDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, CA, USA.
Sidney C HallerDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, CA, USA.
Kirsten N KangelarisDivision of Hospital Medicine, University of California, San Francisco, CA, USA.
Walter L EckalbarDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, CA, USA.
David J ErleDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, CA, USA.
Matthew F KrummelDepartment of Pathology, University of California, San Francisco, CA, USA.ORCID 0000-0001-7915-3533
Carolyn M HendricksonDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, CA, USA.
Prescott G WoodruffDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, CA, USA.
Charles R LangelierChan Zuckerberg Biohub, San Francisco, CA, USA.ORCID 0000-0002-6708-4646
Carolyn S CalfeeDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, CA, USA.
Gabriela K FragiadakisUCSF CoLabs, University of California San Francisco, San Francisco, CA, USA.
University of California, San Francisco · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Understanding Asthma EndotypesU19AI077439 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2008 to 2026
$41.1M
The role of γδ T cells in fetal and infant immune defense against malariaR01AI093615 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FEENEY, MARGARET E · 2011 to 2025
$9.1M
RESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGYP30AR070155 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary C Nakamura · 2016 to 2026
$8.2M
Clinical & Immunological Study of Treatment Withdrawal in E-Ag Negative Hepatitis BR01DK103735 · NIDDK · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI BARON, JODY L, COOPER, STEWART · 2016 to 2025
$7.2M
Precision Medicine in the Acute Respiratory Distress SyndromeR35HL140026 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CALFEE, CAROLYN · 2018 to 2024
$6.8M
Targeting HIV-specific T cell differentiation programs to enhance post-treatment control of HIVR01AI170239 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Rachel Lena Rutishauser · 2022 to 2026
$4.0M
Sjögren's International Collaborative Clinical Alliance Next Generation Studies (SICCA-NextGen)U01DE028891 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHIBOSKI, CAROLINE HELENE · 2020 to 2024
$4.0M
T cell immunity to CMV in utero and in early childhoodU01AI168390 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARGARET E FEENEY · 2022 to 2026
$3.9M
Immune determinants of progression from Oral Epithelial Dysplasia to Oral Squamous Cell Carcinoma by precision multiplexed imagingR01DE032033 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Matthew Spitzer · 2022 to 2026
$3.8M
Evolution and resolution of ARDS molecular phenotypesK23HL163491 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Aartik Sarma · 2023 to 2026
$750k
Transcriptomic signatures of airway inflammation in acute respiratory diseasesF32HL151117 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SARMA, AARTIK · 2020 to 2022
$206k
NHLBI NIH HHS F32 HL151117NHLBI NIH HHS K23 HL163491NHLBI NIH HHS R35 HL140026NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI093615NIAID NIH HHS R01 AI170239NIAID NIH HHS U01 AI168390NIAID NIH HHS U19 AI077439NIAMS NIH HHS P30 AR070155NIDCR NIH HHS R01 DE032033NIDCR NIH HHS U01 DE028891NIDDK NIH HHS R01 DK103735
6 · The paper itself

Abstract

Dexamethasone is the standard of care for critically ill patients with COVID-19, but the mechanisms by which it decreases mortality and its immunological effects in this setting are not understood. We performed bulk and single-cell RNA sequencing of the lower respiratory tract and blood, and plasma cytokine profiling to study the effect of dexamethasone on systemic and pulmonary immune cells. We find decreased signatures of antigen presentation, T cell recruitment, and viral injury in patients treated with dexamethasone. We identify compartment- and cell- specific differences in the effect of dexamethasone in patients with severe COVID-19 that are reproducible in publicly available datasets. Our results highlight the importance of studying compartmentalized inflammation in critically ill patients.

Identifiers

PMID37577607
PMCPMC10418533
OpenAlexW4385551632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.